ISSN: 0950-9232

Oncogene Q1 Unclaimed

Nature Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Oncogene aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research. We propagate work that challenges standard conjecture and builds on previous studies, in particular those that lead to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers, and in processes that drive metastatic spread, and provide important insights into cancer biology beyond what has been revealed thus far. It has an SJR impact factor of 3,395.

Oncogene focuses its scope in these topics and keywords: cancer, cell, human, expression, tumor, gene, regulates, growth, cells, protein, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Genetics (Q1) Molecular Biology (Q1)

Price

4190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

3,395

SJR Impact factor

342

H Index

508

Total Docs (Last Year)

1613

Total Docs (3 years)

27383

Total Refs

14178

Total Cites (3 years)

1601

Citable Docs (3 years)

8,64

Cites/Doc (2 years)

53,9

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Structural & Molecular Biology Q1
Molecular Systems Biology Q1
Cell Host and Microbe Q1
EMBO Journal Q1
Nature Protocols Q1

Compare this journals

Aims and Scope

Best articles by citations

Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1

Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells

REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype

Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells

Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling

Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma

JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity

CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants

Introductory comments

Retinal dysplasia in mice lacking p56lck

Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria

Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness

SHOW MORE ARTICLES

The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP

Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma

Gene expression profiling of ErbB receptor and ligand-dependent transcription

Angiomotin expression promotes hemangioendothelioma invasion

Erratum: Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran

Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells

Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland

Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration

Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

Polo-like kinases, an introduction

Guest Editor

A novel protein, RTN-xS, interacts with both Bcl-xL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity